OMISIRGE
Biological
Gamida Cell Inc.
Total Payments
$937,842
Transactions
95
Doctors
36
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $378,904 | 49 | 28 |
| 2023 | $558,938 | 46 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $711,844 | 39 | 75.9% |
| Consulting Fee | $223,769 | 25 | 23.9% |
| Food and Beverage | $2,229 | 31 | 0.2% |
Payments by Type
Research
$711,844
39 transactions
General
$225,998
56 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STEM CELL TRANSPLANTATION WITH NICORD (OMIDUBICEL) VS STANDARD UCB IN PATIENTS WITH LEUKEMIA, LYMPHOMA, AND MDS | Gamida Cell Inc. | $429,659 | 0 |
| EXPANDED ACCESS OF OMIDUBICEL, FOR ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | Gamida Cell Inc. | $248,458 | 0 |
| LONG TERM FOLLOW UP PROTOCOL FOR NICORD\CORDIN (OMIDUBICEL) PATIENTS | Gamida Cell Inc. | $33,726 | 0 |
Top Doctors Receiving Payments for OMISIRGE — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Rochester, NY | $68.56 | 1 |
| , M D | Pediatric Hematology-Oncology | Rochester, MN | $46.87 | 1 |
| , M.D | Internal Medicine | New York, NY | $45.58 | 1 |
| , MD | Hematology & Oncology | Los Angeles, CA | $43.10 | 1 |
| , MD, PHD | Student in an Organized Health Care Education/Training Program | Los Angeles, CA | $43.10 | 1 |
| Georgia Lill | Internal Medicine | Los Angeles, CA | $43.10 | 1 |
| Rui Li | Student in an Organized Health Care Education/Training Program | Los Angeles, CA | $43.10 | 1 |
| Jonathan Boiarsky | Student in an Organized Health Care Education/Training Program | Los Angeles, CA | $43.10 | 1 |
| , MD | Hematology | Los Angeles, CA | $43.10 | 1 |
| , M.D | Hematology & Oncology | Dallas, TX | $30.15 | 1 |
| , M.D | Internal Medicine | Milwaukee, WI | $30.15 | 1 |
| , MD | Hematology & Oncology | New York, NY | $26.78 | 1 |
Ad
Manufacturing Companies
- Gamida Cell Inc. $937,842
Product Information
- Type Biological
- Total Payments $937,842
- Total Doctors 36
- Transactions 95
About OMISIRGE
OMISIRGE is a biological associated with $937,842 in payments to 36 healthcare providers, recorded across 95 transactions in the CMS Open Payments database. The primary manufacturer is Gamida Cell Inc..
Payment data is available from 2023 to 2024. In 2024, $378,904 was paid across 49 transactions to 28 doctors.
The most common payment nature for OMISIRGE is "Unspecified" ($711,844, 75.9% of total).
OMISIRGE is associated with 3 research studies, including "STEM CELL TRANSPLANTATION WITH NICORD (OMIDUBICEL) VS STANDARD UCB IN PATIENTS WITH LEUKEMIA, LYMPHOMA, AND MDS" ($429,659).